Nakagawa T, Onozuka S, Mayanagi K
Department of Neurosurgery; Keio University School of Medicine, Japan -
Interv Neuroradiol. 2001 Jun 30;7(2):127-30. doi: 10.1177/159101990100700206. Epub 2001 Jul 15.
Anticoagulant therapy is usually used after endovascular operations like coil embolization of aneurysms, or for thromboembolic diseases such as myocardial infarction. Few data exist regarding hemorrhage from benign brain tumors during systemic heparinization with the exception of pituitary adenomas (1,2). We experienced two cases of hemorrhage from benign brain tumors during systemic heparinization. The first patient had an unruptured aneurysm in her suprasellar tumor. She underwent coil embolization to prevent hemorrhage during the subsequent tumorectomy. During and after the endovascular operation, she was heparinized and she suffered a hemorrhage from the tumor on the first postoperative day. The second patient had a suprasellar tumor and was heparinized prophylactically for myocardial infarction. He had an intratumoral hemorrhage on the fifth day after the start of the heparinization. This small series suggests that systemic heparinization with brain tumors, even when they are benign, is very dangerous, and further studies with a larger patient base are warranted.
抗凝治疗通常用于血管内手术后,如动脉瘤的弹簧圈栓塞,或用于血栓栓塞性疾病,如心肌梗死。除垂体腺瘤外,关于全身肝素化期间良性脑肿瘤出血的数据很少(1,2)。我们遇到了两例全身肝素化期间良性脑肿瘤出血的病例。第一例患者的鞍上肿瘤中有一个未破裂的动脉瘤。她接受了弹簧圈栓塞以防止随后肿瘤切除术中出血。在血管内手术期间和之后,她接受了肝素化治疗,并在术后第一天出现肿瘤出血。第二例患者有一个鞍上肿瘤,因心肌梗死接受预防性肝素化治疗。在肝素化开始后的第五天,他发生了肿瘤内出血。这个小系列病例表明,即使是良性脑肿瘤,全身肝素化也是非常危险的,有必要进行更大样本量患者的进一步研究。